Co-Authors
This is a "connection" page, showing publications co-authored by Massimo Andreoni and Giustino Parruti.
Connection Strength
0.372
-
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
Score: 0.189
-
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 06 12; 8(1):8988.
Score: 0.048
-
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 01; 72(12):3420-3424.
Score: 0.047
-
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017; 12(5):e0177352.
Score: 0.045
-
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 04; 37(4):514-528.
Score: 0.044